Oops, you're using an old version of your browser so some of the features on this page may not be displaying properly.

MINIMAL Requirements: Google Chrome 24+Mozilla Firefox 20+Internet Explorer 11Opera 15–18Apple Safari 7SeaMonkey 2.15-2.23

5
ESMO-MCBS v1.1
Scorecard version: 1

Indication details

Tumour Type
Thoracic Malignancies
Tumour Sub-type
Squamous or non-squamous non-small-cell lung cancer
Tumour stage
Metastatic
Control Arm
Docetaxel
Treatment Setting
Squamous or non-squamous stage IIIB or IV patients who had previously received one or two chemotherapy regimes
Trial Name
OAK

Primary Outcome(s)

Primary Outcome(s)
OS
Form(s)
Form 2a

Outcome Data

OS Control
9.6 months
OS Gain
4.2 months
OS HR
0.73 (0.62-0.87)
Toxicity Comment
Improved toxicity profile

Final Score (after adjustments)

Preliminary non-curative score
4
Toxicity adjustment
1+
Final non-curative Score
5
Release date
15.05.2019
Last update
16.03.2020

DFS, disease-free survival; DoR, duration of response; EFS, event-free survival; HR, hazard ratio; iDFS, invasive disease-free survival; ITT, intention to treat; mPFS, median progression-free survival; ORR, overall response rate; OS, overall survival; pCR, pathologic complete response/remission; PFS, progression-free survival; QoL, quality of life; RFS, relapse-free survival; RR, response rate

This site uses cookies. Some of these cookies are essential, while others help us improve your experience by providing insights into how the site is being used.

For more detailed information on the cookies we use, please check our Privacy Policy.

Customise settings